Parity-Violating Electron Scattering from (4)He and the Strange Electric Form Factor of the Nucleon

We have measured the parity-violating electroweak asymmetry in the elastic scattering of polarized electrons from 4He at an average scattering angle ⟨θlab⟩=5.7° and a four-momentum transfer Q2=0.091  GeV2. From these data, for the first time, the strange electric form factor of the nucleon GEs can be isolated. The measured asymmetry of APV=(6.72±0.84(stat)±0.21(syst))×10-6 yields a value ofGEs=-0.038±0.042(stat)±0.010(syst), consistent with zero

Evidence for the Decay Σ+→pμ+μ-

We report the first evidence for the decay Σ+→pμ+μ- from data taken by the HyperCP (E871) experiment at Fermilab. Based on three observed events, the branching ratio is B(Σ+→pμ+μ-)=[8.6-5.4+6.6(stat)±5.5(syst)]×10-8. The narrow range of dimuon masses may indicate that the decay proceeds via a neutral intermediate state, Σ+→pP0,P0→μ+μ- with a P0 mass of 214.3±0.5  MeV/c2 and branching ratio B(Σ+→pP0,P0→μ+μ-)=[3.1-1.9+2.4(stat)±1.5(syst)]×10-8

Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer

Background If patients in oncology trials receive subsequent therapy, standard intention-to-treat (ITT) analyses may inaccurately estimate the overall survival (OS) effect of the investigational product. In this context, a post-hoc analysis of the phase 3 PREVAIL study was performed with the aim to compare enzalutamide with placebo in terms of OS, adjusting for potential confounding from switching to antineoplastic therapies that are not part of standard metastatic castration-resistant prostate cancer (mCRPC) treatment pathways in some jurisdictions. Methods The PREVAIL study, which included 1717 chemotherapy-naïve men with mCRPC randomized to treatment with enzalutamide 160 mg/day or placebo, was stopped after a planned interim survival analysis revealed a benefit in favor of enzalutamide. Data from this cutoff point were confounded by switching from both arms and so were evaluated in terms of OS using two switching adjustment methods: the two-stage accelerated failure time model (two-stage method) and inverse probability of censoring weights (IPCW). Results Following adjustment for switching to nonstandard antineoplastic therapies by 14.8 (129/872 patients) and 21.3% (180/845 patients) of patients initially randomized to enzalutamide and placebo, respectively, the two-stage and IPCW methods both resulted in numerical reductions in the hazard ratio (HR) for OS [HR 0.66, 95% confidence interval (CI) 0.57–0.81 and HR 0.63, 95% CI 0.52–0.75, respectively] for enzalutamide compared to placebo versus the unadjusted ITT analysis (HR 0.71, 95% CI 0.60–0.84). These results suggest a slightly greater effect of enzalutamide on OS than originally reported. Conclusion In the PREVAIL study, switching to nonstandard antineoplastic mCRPC therapies resulted in the ITT analysis of primary data underestimating the benefit of enzalutamide on OS

Spectroscopy of Li-9(Lambda) by electroproduction

Background: In the absence of accurate data on the free two-body hyperon-nucleon interaction, the spectra of hypernuclei provides information on the details of the effective hyperon-nucleon interaction. Purpose: To obtain a high-resolution binding-energy spectrum for the Be-9(e, e\u27 K+) Li-9(Lambda) reaction. Method: Electroproduction of the hypernucleus Li-9(Lambda) has been studied for the first time with sub-MeV energy resolution in Hall A at Jefferson Lab on a Be-9 target. In order to increase the counting rate and to provide unambiguous kaon identification, two superconducting septum magnets and a ring imaging Cherenkov detector were added to the Hall A standard equipment. Results: The cross section to low-lying states of Li-9(Lambda) is concentrated within 3 MeV of the ground state and can be fit with four peaks. The positions of the doublets agree with theory while a disagreement could exist with respect to the relative strengths of the peaks in the doublets. The Lambda separation energy, B-Lambda, of 8.36 +/- 0.08 (stat.) +/- 0.08 (syst.) MeV was measured, in agreement with an earlier experiment

Search for the Lepton-Number-Violating Decay Ξ−→pμ−μ−\Xi^- \to p \mu^- \mu^-

A sensitive search for the lepton-number-violating decay $\Xi^-\to p \mu^-\mu^-$ has been performed using a sample of $\sim10^9$ $\Xi^-$ hyperons produced in 800 GeV/$c$ $p$-Cu collisions. We obtain $\mathcal{B}(\Xi^-\to p \mu^-\mu^-)< 4.0\times 10^{-8}$ at 90% confidence, improving on the best previous limit by four orders of magnitude.Comment: 9 pages, 5 figures, to be published in Phys. Rev. Let

Measurement of the Alpha Asymmetry Parameter for the Omega- to Lambda K- Decay

We have measured the alpha parameter of the Omega- to Lambda K- decay using data collected with the HyperCP spectrometer during the 1997 fixed-target run at Fermilab. Analyzing a sample of 0.96 million Omega- to Lambda K^-, Lambda to p pi- decays, we obtain alpha_Omega*alpha_Lambda = [1.33+/-0.33(stat)+/-0.52(syst)] x 10^{-2}. With the accepted value of alpha_Lambda, alpha_Omega is found to be [2.07+/-0.51(stat)+/-0.81(syst)] x 10^{-2}.Comment: 5 pages, 4 figures, to be appeared as a Rapid Communication in Phys. Rev.